Skip to content

Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study

Effects of Lentinula Edodes Bar on Lipid Profile and Antioxidant Status in Borderline High Cholesterol Individuals: a Double Blind Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04186780
Enrollment
68
Registered
2019-12-05
Start date
2018-09-26
Completion date
2019-09-20
Last updated
2020-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias

Keywords

Lentinula edodes, Clinical study, Cholesterolemia, Nutraceuticals

Brief summary

The daily change in population routine has stimulated the development of health beneficial value added products. Lentinula edodes (Shiitake) is a mushroom with high protein concentration, low lipid content, rich in fiber, minerals, vitamins, antioxidant compounds, β-glucans and chitosan. This is clinical study phase II, randomized, double-blind for analyze in the effect of eating Shiitake bars on cholesterolemia and oxidative stress levels in individuals with borderline cholesterol. Individuals with at least one of the following biochemical markers (total cholesterol, LDL or triglycerides) at the borderline level were recruited through online questionnaire. Individuals (n = 68) were randomly allocated to two groups (Group I - Shiitake free bar (n = 32); Group II - Shiitake bar (n = 36). Each individual underwent blood collection at 0, 33 and 66 days, and received an unidentified opaque bag containing the bars.Biochemical analyzes (triglycerides, total cholesterol, LDL, HDL and glucose) and oxidative stress markers (Catalase, GSH and TBARS) were performed on samples of individuals.

Detailed description

Study design The primary outcome of the study was cholesterolemia, as assessed by total cholesterol levels, triglycerides or low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The secondary outcomes included blood glucose, Body Mass Index (BMI) and oxidative stress biomarkers. A prospective Phase II, randomized, double blind and placebo-controlled trial was conducted from September 2018 to December 2018. The study accomplished at University of Sorocaba (UNISO), São Paulo State, Brazil. The study was approved (Annex D) by Human Research Ethics Committee from University of Sorocaba (protocol number 2.824.297), in accordance with Resolution 466/2012 of the National Health Council (BRASIL, 2012) and Research Ethics Review Committee (ERC) (WHO, 2016). Recruitment of individuals For the recruitment of individuals, the disclosure was initiated five months before the start of Phase II trial. The research was published on the website of the University of Sorocaba (UNISO), on social media and folders distributed throughout campus containing a brief explanation about the research, inclusion and exclusion criteria, and contact of the researcher. According to the Resolution 1.170, from Anvisa (National Health Surveillance Agency), Phase II studies are not allowed with less than 12 people; however, the Agency suggests using a minimum of 24 volunteers. Eligibility Criteria A total of 165 individuals completed the Google online survey. * Inclusion Criteria Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; triglycerides of 150 to 200 mg/dL), were recruited, diagnosed by biochemical exams with dates recent to the day of recruitment. The be tolerant to bars ingredients and to Shiitake. Availability to attend the date and time of blood collection. * Exclusion Criteria However, some of them had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be considered as confounders of the study and some recruited people had to be excluded. Pregnant, lactating or hormone replacement women could not participate either. Individuals were instructed to no change their eating habits and patterns, physical activity level or oral contraceptive use during the study, thus identifying only the effects of Shiitake added to the diet for each individual on the exposed group. Study Interventions. The study officially started with 68 individuals, who signed an informed term of consent. In the first (Time 0 - T0), in the second (Time 33 days - T33) and in the third (Time 66 days - T66) meetings, the subjects were submitted to nutritional assessment and anamnesis, 24-hour recall of eating habits and eating frequency. In the first month of the study 4,100 placebo or mushroom bars were produced and in the second month the production was 3,500 bars. According to the Grotto and collaborators (2015), conducted a study evaluating different Shiitake concentrations (100, 400 and 800 mg/Kg/day) to determine the degree of toxicity in animals. Shiitake concentration of 100 mg/Kg/day has been shown to be safe. Besides, the Shiitake sweet bar formulation was approved in the sensory analysis and purchase intention in the previous study. Randomization The individuals (68) were randomly allocated (using a table of random numbers) into 2 groups: I - Placebo group (n = 32) and II - Intervention group (n = 36). To ensure the daily recommended intake of Shiitake of 100 mg/Kg/day, each participant was weighted to determine the number of bars consumed per day. The Individuals after nutritional assessment and blood collection, received an unidentified opaque and sealed packed containing individually vacuum bars for a period of T33 days. The patients and the data collector were blind. The bars of the intervention and placebo groups were similar in texture, flavor, aroma and appearance. After one month, all individuals returned to the University of Sorocaba for new nutritional assessments, receiving more food bars and blood collection with the same double-blind care (T33). At the end of sixty-six days (T66), subjects returned for the last blood collection and final nutritional assessment. Biochemical Analysis Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose were analyzed by commercial kits, following the manufacturer's specifications, in the automated equipment COBAS C111 (Roche®) according to the methodologies below. For cholesterol, 10 µL of sample and 1.0 mL of enzyme reagent were mixed at 37 ºC for 10 min for total transformation into free cholesterol, by lipoprotein lipase enzyme. The reaction involved the oxidation of free cholesterol to cholesterol-3-one and H2O2 by the cholesterol oxidase enzyme. And with the action of peroxidase on phenol with 4-aminoantipyrine formed a cherry chromogen, the color being proportional to the concentration of cholesterol. For the determination of HDL, the serum was treated with phosphotungstate acid and magnesium chloride. So, the LDL was precipitated out from the fraction after centrifugation for 2 min at 10.000 rpm. HDL, which remained in the supernatant, was performed according to the cholesterol methodology. HDL concentration is proportional to the color. LDL was calculated by subtracting HDL cholesterol from total cholesterol. Serum triglycerides were hydrolyzed to glycerol and free fatty acid by lipoprotein lipase. In the presence of adenosine triphosphate (ATP) and glycerol kinase, glycerol-3-phosphate was phosphorylated, which was oxidized to acetone dihydrogen phosphate and H2O2 by the glycerol phosphate oxidase. H2O2, 4-aminoantipyrine and p-chlorophenol underwent the same reaction process reported above by peroxidase in a 37 ºC water bath for 10 minutes until formation of red color. For the blood glucose test, glucose-6-phosphate dehydrogenase oxidized glucose-6-phosphate in the presence of NADP in gluconate-6-phosphate. No other carbohydrates have been oxidized. The rate of NADPH formation during the reaction was directly proportional to the glucose concentration, being determined photometrically. Oxidative Stress Analysis The determination of reduced glutathione (GSH) was made by quantification of reduced total thiols based. For this, 150 µL of the blood was vortexed with 100 µL 10% Triton X-100 and 100 µL 30% TCA, then centrifuged for 10 min at 4000 rpm. In the cuvette 900 µL of 1M TFK, 50 µL of supernatant, and 50 µL of 10 mM DTNB were pipetted, which reacted to form a yellow complex. The reading was taken at 412 nm in a spectrophotometer. For the calculation of concentration, the calibration curve with predefined GSH concentrations (0.005; 0.01; 0.025; 0.05; 0.1 mM) was used. To evaluate the activity of the catalase enzyme was used, based on the decomposition of H2O2 by catalase, monitored at 240 nm. For this, the blood was diluted 60 times in 50 mM TFK. An aliquot of 20 μL was mixed to 1910 μL of the same TFK, and 70 μL of H2O2 was added, initiating the monitored reaction for three minutes. A constant of variation (κ) per minute helped in the expression of catalase enzyme (κ/min). Thiobarbituric acid reactive substances (TBARS) were used as a biomarker of lipid peroxidation. Plasma aliquots (150 µL) were mixed with 50 µL NaOH and 50 µL Milli-Q ultrapure water (Direct 8, Millipore®) and incubated at 60 °C for 30 minutes with shaking. 250 µL of 6% H₃PO₄, 250 µL of 0.8% TBA and 100 µL of 10% SDS were added to the samples and taken to the 80 °C bath for one hour. Lipid peroxides reacted with TBA in acidic medium to form a pink compound and read in a spectrophotometer at 532 nm. To calculate the concentration of TBARS in plasma, a calibration curve of malondialdehyde, the main thiobarbituric acid reactive substance, was made (0.28; 0.56; 1.7; 3.4; 6.6 µM).

Interventions

OTHERShiitake cereal bar

patients with borderline cholesterol exposed to bars with Shiitake

Sponsors

University of Sorocaba
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Participants will not be informed to which group they belong, intervention or control. Who will do the randomization will not be blind, because during treatment she will know which group is eating the bars with Shiitake. The researcher responsible for the pre- and post-treatment evaluation will be blind and will not know the research intervention.

Intervention model description

Prospective, randomized, double blind and placebo-controlled

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; triglycerides of 150 to 200 mg/dL), were recruited, diagnosed by biochemical exams with dates recent to the day of recruitment. The be tolerant to bars ingredients and to Shiitake. Availability to attend the date and time of blood collection.

Exclusion criteria

* However, some of them had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be considered as confounders of the study and some recruited people had to be excluded. Pregnant, lactating or hormone replacement women could not participate either. Individuals were instructed to no change their eating habits and patterns, physical activity level or oral contraceptive use during the study, thus identifying only the effects of Shiitake added to the diet for each individual on the exposed group

Design outcomes

Primary

MeasureTime frameDescription
Total Cholesterol LevelsAssessed at 0, 33 and 66 days. Days 0 and 66 reported.Total cholesterol It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).
Triglycerides LevelsAssessed at 0, 33 and 66 days. Days 0 and 66 reported.The triglycerides levels It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Secondary

MeasureTime frameDescription
Oxidative Stress: CatalaseAssessed at 0, 33 and 66 days. Days 0 and 66 reported.The activity of the catalase enzyme was based on the decomposition of H2O2, monitored at 240 nm. A constant of variation or coefficient of variation (κ) per minute helped in the expression of catalase enzyme (κ/min). The Catalase enzyme has the responsibility to break down hydrogen peroxide. Higher scores mean a better outcome. Were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).
Oxidative Stress: Reduced Glutathione (GSH)Assessed at 0, 33 and 66 days. Days 0 and 66 reported.Reduced Glutathione was analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).
Oxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)Assessed at 0, 33 and 66 days. Days 0 and 66 reported.Reactive Substances to Thiobarbituric Acid were analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Countries

Brazil

Participant flow

Recruitment details

The patients were received in September, October and November in the nursing room at the University for the meetings.

Pre-assignment details

Individuals aged from 20 to 65 years old, who had at least one of the following biochemical markers at the borderline level, were recruited. Must be tolerant to bars ingredients and to Shiitake and they must be availability to attend the date and time of blood collection. Some of the individuals had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be confounders of the study and some recruited people had to be excluded.

Participants by arm

ArmCount
Intervention Group
Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days. Shiitake cereal bar: patients with borderline cholesterol exposed to bars with Shiitake
36
Placebo Group
Patients with borderline cholesterol consumed two placebo cereal bars for 66 days. Cereal bar: patients with borderline cholesterol exposed to placebo cereal bars.
32
Total68

Baseline characteristics

CharacteristicIntervention GroupPlacebo GroupTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
36 Participants32 Participants68 Participants
Age, Continuous42 Years
STANDARD_DEVIATION 12
38 Years
STANDARD_DEVIATION 11
40 Years
STANDARD_DEVIATION 11
BMI - Body mass index26.4 kg/m²
STANDARD_DEVIATION 4.4
27.5 kg/m²
STANDARD_DEVIATION 4.4
26.9 kg/m²
STANDARD_DEVIATION 4.4
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
36 Participants32 Participants68 Participants
Measure Smoker tobacco2 Participants4 Participants6 Participants
Number of Participants Reporting Alcohol Consumption19 Participants14 Participants33 Participants
Number of Participants Reporting Regular Physical Activity14 Participants17 Participants31 Participants
Region of Enrollment
Brazil
36 Participants32 Participants68 Participants
Sex: Female, Male
Female
30 Participants23 Participants53 Participants
Sex: Female, Male
Male
6 Participants9 Participants15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 360 / 32
other
Total, other adverse events
7 / 360 / 32
serious
Total, serious adverse events
0 / 360 / 32

Outcome results

Primary

Total Cholesterol Levels

Total cholesterol It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Population: Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline high level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; TG of 150 to 200 mg/dL)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo GroupTotal Cholesterol LevelsTotal Cholesterol T0222.8 mg/dLStandard Deviation 33.1
Placebo GroupTotal Cholesterol LevelsTotal Cholesterol T66226.7 mg/dLStandard Deviation 41.3
Intervention GroupTotal Cholesterol LevelsTotal Cholesterol T0228.2 mg/dLStandard Deviation 45.4
Intervention GroupTotal Cholesterol LevelsTotal Cholesterol T66229.6 mg/dLStandard Deviation 38.2
p-value: 0.59ANOVA
Primary

Triglycerides Levels

The triglycerides levels It was analyzed by commercial kits, according to the manufacturer's specifications. The volunteers' Total Cholesterol and Triglyceride levels were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Population: Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline high level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; TG of 150 to 200 mg/dL)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo GroupTriglycerides LevelsTriglycerides T0144.5 mg/dLStandard Deviation 70.2
Placebo GroupTriglycerides LevelsTriglycerides T66207.7 mg/dLStandard Deviation 202.7
Intervention GroupTriglycerides LevelsTriglycerides T0178.9 mg/dLStandard Deviation 170.1
Intervention GroupTriglycerides LevelsTriglycerides T66160.7 mg/dLStandard Deviation 94.7
p-value: 0.0352ANOVA
Secondary

Oxidative Stress: Catalase

The activity of the catalase enzyme was based on the decomposition of H2O2, monitored at 240 nm. A constant of variation or coefficient of variation (κ) per minute helped in the expression of catalase enzyme (κ/min). The Catalase enzyme has the responsibility to break down hydrogen peroxide. Higher scores mean a better outcome. Were analyzed at Time 0 (when starting the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Population: Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline high level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; TG of 150 to 200 mg/dL)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo GroupOxidative Stress: CatalaseCatalase T03.5 k/minStandard Deviation 1.1
Placebo GroupOxidative Stress: CatalaseCatalase T663.7 k/minStandard Deviation 1.6
Intervention GroupOxidative Stress: CatalaseCatalase T03.1 k/minStandard Deviation 0.8
Intervention GroupOxidative Stress: CatalaseCatalase T663.7 k/minStandard Deviation 2
p-value: 0.8284ANOVA
Secondary

Oxidative Stress: Reduced Glutathione (GSH)

Reduced Glutathione was analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Population: Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline high level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; TG of 150 to 200 mg/dL)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo GroupOxidative Stress: Reduced Glutathione (GSH)GSH T00.4 mMStandard Deviation 0.1
Placebo GroupOxidative Stress: Reduced Glutathione (GSH)GSH T660.6 mMStandard Deviation 0.2
Intervention GroupOxidative Stress: Reduced Glutathione (GSH)GSH T00.4 mMStandard Deviation 0.2
Intervention GroupOxidative Stress: Reduced Glutathione (GSH)GSH T660.5 mMStandard Deviation 0.2
p-value: 0.0058ANOVA
Secondary

Oxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)

Reactive Substances to Thiobarbituric Acid were analyzed in the volunteers' samples at Time 0 (at the beginning of the study), at Time 33 (after 33 days) and at Time 66 (after 66 days).

Time frame: Assessed at 0, 33 and 66 days. Days 0 and 66 reported.

Population: Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline high level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; TG of 150 to 200 mg/dL)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo GroupOxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)TBARS T013.9 µMStandard Deviation 2.3
Placebo GroupOxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)TBARS T6614.7 µMStandard Deviation 2
Intervention GroupOxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)TBARS T014.6 µMStandard Deviation 2.1
Intervention GroupOxidative Stress: Thiobarbituric Acid Reactive Substances (TBARS)TBARS T6613.9 µMStandard Deviation 2.9
p-value: 0.0384ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026